BIIB
Neutral signalScored 2026-09-20 Drivers: Congress, trend, fundamentals. Insiders: neutral. Moteurs : Congrès, tendance, fondamentaux. Initiés : neutre.
Research, not advice.
À propos
Biogen Inc.
- Nom
- Biogen Inc.
- Secteur
- Healthcare
- Industrie
- Drug Manufacturers - General
- Bourse
- NASDAQ
- Capitalisation
- $37.2B
- Employés
- 7,500
- PDG
- Christopher A. Viehbacher
- Site web
- https://www.biogen.com
- Marché
- ALNYAMGNAZNIONSLLYPFE
Biogen Inc. is a leading biotechnology firm dedicated to the discovery, development, production, and distribution of treatments for complex neurological and neurodegenerative conditions. Its established portfolio includes a range of medications addressing multiple sclerosis (MS), such as TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA. For spinal muscular atrophy (SMA), Biogen provides SPINRAZA, while FUMADERM is available for the treatment of plaque psoriasis. Among its other key offerings is ADUHELM, specifically developed for Alzheimer's disease. The company also markets a selection of biosimilar drugs, including BENEPALI (an etanercept biosimilar akin to ENBREL), IMRALDI (an adalimumab biosimilar comparable to HUMIRA), and FLIXABI (an infliximab biosimilar referencing REMICADE). Further extending its therapeutic reach, Biogen supplies RITUXAN, prescribed for conditions like non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, certain types of ANCA-associated vasculitis, and pemphigus vulgaris. RITUXAN HYCELA targets non-Hodgkin's lymphoma and CLL, and GAZYVA is utilized for CLL and follicular lymphoma. OCREVUS addresses both relapsing and primary progressive forms of MS, complementing the company's broader efforts in anti-CD20 therapies. The company maintains a robust research and development pipeline, featuring numerous investigational therapies. These candidates are designed to tackle a wide spectrum of conditions, including multiple sclerosis and neuroimmunological disorders (e.g., BIIB135, BIIB061, BIIB091, BIIB107), Alzheimer's disease and other forms of dementia (e.g., Aducanumab, Lecanemab, BIIB076, BIIB080), neuromuscular disorders (e.g., BIIB067, BIIB078, BIIB105, BIIB100, BIIB110), Parkinson's disease and related movement disorders (e.g., BIIB124, BIIB094, BIIB118, BIIB101, BIIB122), neuropsychiatric conditions (e.g., BIIB125, BIIB104), immunology-related illnesses (e.g., Dapirolizumab pegol, BIIB059), acute neurological events (e.g., BIIB093, BIIB131), and neuropathic pain (e.g., BIIB074). Additionally, several biosimilar candidates, such as BYOOVIZ, BIIB800, and SB15, are progressing through various developmental stages. Biogen actively engages in strategic collaborations and licensing arrangements with various partners, including Acorda Therapeutics, Inc., Alkermes Pharma Ireland Limited, Denali Therapeutics Inc., Eisai Co., Ltd., Genentech, Inc., Neurimmune SubOne AG, Ionis Pharmaceuticals, Inc., Samsung Bioepis Co., Ltd., Sangamo Therapeutics, Inc., and Sage Therapeutics, Inc. Established in 1978, Biogen Inc. maintains its corporate headquarters in Cambridge, Massachusetts.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 1 186 titres (~239 749,90 $ US)
- Insiders
- Minor Lloyd
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$239,750
Avg sell (VWAP, 90d window) $202.15 vs last close $219.88 (+8.8%)
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
$239,750 of that total is under a Rule 10b5-1 plan. It is shown here and left out of the score.
- Last activity
- 2026-08-04
- Liquidity
- Liquid $234,828,168/day · 20d vol
- Last synced
-
2026-10-02 21:10:10
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-08-04 | Minor Lloyd | Sell · S · 10b5-1 | 593 | $200.96 | $119,169 | Form 4 |
| 2026-08-03 | Minor Lloyd | Sell · S · 10b5-1 | 593 | $203.34 | $120,581 | Form 4 |
Sales marked 10b5-1 are scheduled in advance and don't count toward the Quorum score. Les ventes marquées 10b5-1 sont planifiées à l'avance et ne pèsent pas dans le score Quorum.
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2026-06-05 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2026-06-02 | Maria Elvira Salazar | Sale | $15,001 - $50,000 |
| 2026-05-12 | Maria Elvira Salazar | Purchase | $1,001 - $15,000 |
| 2026-05-11 | Maria Elvira Salazar | Purchase | $1,001 - $15,000 |
| 2026-05-11 | Maria Elvira Salazar | Purchase | $50,001 - $100,000 |
| 2026-01-30 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2025-08-26 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2025-05-15 | Rob Bresnahan | Purchase | $1,001 - $15,000 |
| 2025-04-08 | Rob Bresnahan | Sale (Full) | $1,001 - $15,000 |
| 2025-02-25 | Rob Bresnahan | Purchase | $1,001 - $15,000 |
| 2024-11-15 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2024-09-09 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2024-09-09 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2024-03-25 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2024-03-20 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2024-02-13 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2024-01-10 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-11-03 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-10-10 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-10-02 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-09-06 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-08-29 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-04-10 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-03-06 | Daniel Goldman | Sale (Partial) | $1,001 - $15,000 |
| 2023-02-10 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-01-09 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-12-06 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-11-03 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-08-23 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-08-03 | Kathy Manning | Sale (Full) | $1,001 - $15,000 |
| 2022-08-01 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-07-20 | Kathy Manning | Purchase | $1,001 - $15,000 |
| 2022-06-17 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-05-23 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-05-10 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-04-21 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-04-11 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-03-17 | Josh Gottheimer | Sale (Full) | $1,001 - $15,000 |
| 2022-02-17 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-02-14 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-01-21 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-01-20 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-01-14 | Kathy Manning | Sale (Full) | $1,001 - $15,000 |
| 2022-01-11 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-01-10 | Josh Gottheimer | Purchase | $1,001 - $15,000 |
| 2021-12-09 | Josh Gottheimer | Sale (Partial) | $1,001 - $15,000 |
| 2021-10-18 | Josh Gottheimer | Purchase | $1,001 - $15,000 |
| 2021-09-15 | Josh Gottheimer | Sale (Partial) | $1,001 - $15,000 |
| 2021-06-08 | Josh Gottheimer | Purchase | $1,001 - $15,000 |
| 2021-02-16 | Peter Meijer | Sale (Full) | $15,001 - $50,000 |
| 2021-01-04 | Chris Jacobs | Sale (Full) | $1,001 - $15,000 |
| 2020-12-22 | Gilbert Cisneros | Sale (Full) | $1,001 - $15,000 |
| 2020-09-16 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2020-07-07 | Josh Gottheimer | Purchase | $1,001 - $15,000 |
| 2020-04-29 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2020-03-18 | Gilbert Cisneros | Sale (Full) | $1,001 - $15,000 |
| 2020-02-07 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2019-06-24 | Donna Shalala | Sale (Full) | $1,001 - $15,000 |
| 2019-06-20 | Dean Phillips | Purchase | $1,001 - $15,000 |
| 2018-10-29 | Josh Gottheimer | Sale (Full) | $1,001 - $15,000 |
| 2018-10-05 | Gary Palmer | Sale (Full) | $1,001 - $15,000 |
Signal
Neutral signalScored 2026-09-20 Drivers: Congress, trend, fundamentals. Insiders: neutral. Moteurs : Congrès, tendance, fondamentaux. Initiés : neutre.
Biogen presents a compelling near-term event-driven opportunity, supported by a strong earnings beat, raised 2026 guidance, and a strategic acquisition of RayThera Inc., all backed by solid liquidity (score: 85) and a…
The first sentence of the analysis written for BIIB on 2026-09-20 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Unavailable or mixed. – Insider: neutral. All sales (≈ $240K) were pre-planned Rule 10b5-1 trades, excluded from the score. No open-market buys or discretionary sales. – Initiés : neutre. Toutes les ventes (≈ $240K) sont sous plan 10b5-1 préétabli, exclues du score. Aucun achat ni vente discrétionnaire.
- Congress Pulls against a bullish reading. STOCK Act sale disclosures outnumber purchases
- Narrative Supports a bullish reading. Stored narrative reading is in the bullish band
- Timing Supports a bullish reading. Interesting trend — weekly bias up
- Financial indicators Supports a bullish reading. Current ratio 2.68 · operating margin 19%
Suggested stop 211.66, nearest stored support minus 0.5 ATR(3.7% under the last close). Reward/risk to the next stored resistance is 0.45. Wait — that reward/risk is under 2. Research, not advice. Not an order.
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 70.5% | 76.1% | 74.2% | 77.6% | 80.8% | |
| Ebit Margin | 22.1% | 24.0% | 19.1% | 29.7% | 31.3% | |
| Ebitda Margin | 31.6% | 31.0% | 24.2% | 34.8% | 35.7% | |
| Operating Profit Margin | 19.1% | 25.7% | 21.3% | 28.4% | 25.4% | |
| Pretax Profit Margin | 14.3% | 19.7% | 13.2% | 35.3% | 16.2% | |
| Continuous Operations Profit Margin | 13.2% | 16.9% | 11.8% | 29.1% | 15.7% | |
| Net Profit Margin | 13.2% | 16.9% | 11.8% | 29.9% | 14.2% | |
| Bottom Line Profit Margin | 13.2% | 16.9% | 11.8% | 29.9% | 14.2% | |
| Current Ratio | 2.679 | 1.349 | 1.997 | 2.992 | 1.828 | |
| Quick Ratio | 2.032 | 0.904 | 1.261 | 2.581 | 1.513 | |
| Solvency Ratio | 0.199 | 0.203 | 0.137 | 0.319 | 0.158 | |
| Cash Ratio | 0.898 | 0.430 | 0.306 | 1.045 | 0.526 | |
| Price To Earnings Ratio | 19.886 | 13.654 | 32.266 | 13.206 | 22.981 | |
| Price To Earnings Growth Ratio | -0.948 | 0.344 | -0.522 | 0.131 | -0.396 | |
| Forward Price To Earnings Growth Ratio | -0.948 | 0.344 | -0.522 | 0.131 | -0.396 | |
| Price To Earnings Diluted Ratio | 19.931 | 13.666 | 32.468 | 13.269 | 23.069 | |
| Price To Earnings Diluted Growth Ratio | -0.945 | 0.338 | -0.525 | 0.132 | -0.397 | |
| Price To Book Ratio | 1.414 | 1.333 | 2.530 | 3.003 | 3.283 | |
| Price To Sales Ratio | 2.632 | 2.303 | 3.807 | 3.955 | 3.257 | |
| Price To Free Cash Flow Ratio | 12.589 | 8.857 | 30.299 | 35.172 | 10.578 | |
| Price To Operating Cash Flow Ratio | 11.711 | 7.748 | 24.201 | 29.066 | 9.828 | |
| Debt To Assets Ratio | 0.236 | 0.236 | 0.273 | 0.269 | 0.318 | |
| Debt To Equity Ratio | 0.381 | 0.397 | 0.496 | 0.494 | 0.698 | |
| Debt To Capital Ratio | 0.276 | 0.284 | 0.331 | 0.331 | 0.411 | |
| Long Term Debt To Capital Ratio | 0.265 | 0.214 | 0.314 | 0.319 | 0.365 | |
| Financial Leverage Ratio | 1.613 | 1.678 | 1.814 | 1.833 | 2.191 | |
| Working Capital Turnover Ratio | 2.598 | 3.615 | 1.978 | 2.019 | 3.277 | |
| Operating Cash Flow Ratio | 0.658 | 0.520 | 0.451 | 0.423 | 0.847 | |
| Operating Cash Flow Sales Ratio | 0.225 | 0.297 | 0.157 | 0.136 | 0.331 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.930 | 0.875 | 0.799 | 0.826 | 0.929 | |
| Debt Service Coverage Ratio | 9.168 | 1.362 | 5.648 | 11.777 | 3.090 | |
| Interest Coverage Ratio | 7.632 | 9.949 | 8.495 | 11.716 | 11.007 | |
| Short Term Operating Cash Flow Coverage Ratio | 27.420 | 1.644 | 10.315 | 0.000 | 3.643 | |
| Operating Cash Flow Coverage Ratio | 0.317 | 0.434 | 0.211 | 0.209 | 0.479 | |
| Capital Expenditure Coverage Ratio | 14.334 | 7.992 | 4.969 | 5.761 | 14.103 | |
| Dividend Paid And Capex Coverage Ratio | 14.334 | 7.992 | 4.969 | 5.761 | 14.103 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | 9.597 | 8.858 | 18.398 | 12.279 | 10.479 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 70.5% | ▼-5.7% | ▼-5.4% |
| Ebit Margin | 22.1% | ▼-1.9% | ▼-3.2% |
| Ebitda Margin | 31.6% | ▲0.6% | ▲0.2% |
| Operating Profit Margin | 19.1% | ▼-6.6% | ▼-4.9% |
| Pretax Profit Margin | 14.3% | ▼-5.4% | ▼-5.5% |
| Continuous Operations Profit Margin | 13.2% | ▼-3.7% | ▼-4.2% |
| Net Profit Margin | 13.2% | ▼-3.7% | ▼-4.0% |
| Bottom Line Profit Margin | 13.2% | ▼-3.7% | ▼-4.0% |
| Current Ratio | 2.679 | ▲1.331 | ▲0.510 |
| Quick Ratio | 2.032 | ▲1.128 | ▲0.374 |
| Solvency Ratio | 0.199 | ▼-0.004 | ▼-0.004 |
| Cash Ratio | 0.898 | ▲0.469 | ▲0.257 |
| Price To Earnings Ratio | 19.886 | ▲6.232 | ▼-0.512 |
| Price To Earnings Growth Ratio | -0.948 | ▼-1.292 | ▼-0.669 |
| Forward Price To Earnings Growth Ratio | -0.948 | ▼-1.292 | ▼-0.669 |
| Price To Earnings Diluted Ratio | 19.931 | ▲6.265 | ▼-0.550 |
| Price To Earnings Diluted Growth Ratio | -0.945 | ▼-1.283 | ▼-0.665 |
| Price To Book Ratio | 1.414 | ▲0.081 | ▼-0.898 |
| Price To Sales Ratio | 2.632 | ▲0.329 | ▼-0.559 |
| Price To Free Cash Flow Ratio | 12.589 | ▲3.732 | ▼-6.910 |
| Price To Operating Cash Flow Ratio | 11.711 | ▲3.962 | ▼-4.800 |
| Debt To Assets Ratio | 0.236 | ▼-0.000 | ▼-0.031 |
| Debt To Equity Ratio | 0.381 | ▼-0.016 | ▼-0.112 |
| Debt To Capital Ratio | 0.276 | ▼-0.008 | ▼-0.051 |
| Long Term Debt To Capital Ratio | 0.265 | ▲0.051 | ▼-0.031 |
| Financial Leverage Ratio | 1.613 | ▼-0.066 | ▼-0.213 |
| Working Capital Turnover Ratio | 2.598 | ▼-1.017 | ▼-0.100 |
| Operating Cash Flow Ratio | 0.658 | ▲0.138 | ▲0.079 |
| Operating Cash Flow Sales Ratio | 0.225 | ▼-0.072 | ▼-0.005 |
| Free Cash Flow Operating Cash Flow Ratio | 0.930 | ▲0.055 | ▲0.058 |
| Debt Service Coverage Ratio | 9.168 | ▲7.806 | ▲2.959 |
| Interest Coverage Ratio | 7.632 | ▼-2.317 | ▼-2.128 |
| Short Term Operating Cash Flow Coverage Ratio | 27.420 | ▲25.776 | ▲18.816 |
| Operating Cash Flow Coverage Ratio | 0.317 | ▼-0.116 | ▼-0.013 |
| Capital Expenditure Coverage Ratio | 14.334 | ▲6.342 | ▲4.903 |
| Dividend Paid And Capex Coverage Ratio | 14.334 | ▲6.342 | ▲4.903 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | 9.597 | ▲0.739 | ▼-2.325 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $25.82B | $22.28B | $37.44B | $40.24B | $35.77B | |
| Enterprise value | $29.76B | $26.54B | $43.73B | $43.43B | $41.11B | |
| EV / Sales | 3.03x | 2.74x | 4.45x | 4.27x | 3.74x | |
| EV / Op. cash flow | 13.50x | 9.23x | 28.27x | 31.37x | 11.29x | |
| EV / Free cash flow | 14.51x | 10.55x | 35.39x | 37.96x | 12.16x | |
| EV / EBITDA | 9.60x | 8.86x | 18.40x | 12.28x | 10.48x | |
| Net debt / EBITDA | 1.27x | 1.42x | 2.65x | 0.90x | 1.36x | |
| Current ratio | 2.68x | 1.35x | 2.00x | 2.99x | 1.83x | |
| Income quality | 1.71x | 1.76x | 1.33x | 0.47x | 2.11x | |
| Graham number | $157 | $170 | $136 | $209 | $131 | |
| Graham net-net | -$33 | -$43 | -$56 | -$28 | -$47 | |
| Tax burden | 92.3% | 85.6% | 89.5% | 84.8% | 87.4% | |
| Interest burden | 64.7% | 82.1% | 68.9% | 119.1% | 51.8% | |
| Working capital | $5.62B | $1.93B | $3.42B | $6.52B | $3.56B | |
| Invested capital | $24.62B | $21.64B | $21.74B | $17.82B | $15.33B | |
| Return on assets | 4.4% | 5.8% | 4.3% | 12.4% | 6.5% | |
| Operating ROA | 6.5% | 9.1% | 8.2% | 11.9% | 11.5% | |
| Return on tangible assets | 9.4% | 13.7% | 9.5% | 18.0% | 9.8% | |
| Return on equity | 7.1% | 9.8% | 7.8% | 22.7% | 14.3% | |
| Return on invested capital | 6.6% | 8.8% | 8.0% | 11.2% | 13.2% | |
| Return on capital employed | 7.2% | 11.1% | 9.0% | 13.6% | 14.3% | |
| Earnings yield | 5.0% | 7.3% | 3.1% | 7.6% | 4.4% | |
| Free cash flow yield | 7.9% | 11.3% | 3.3% | 2.8% | 9.5% | |
| Capex / Op. cash flow | 7.0% | 12.5% | 20.1% | 17.4% | 7.1% | |
| Capex / Depreciation | 19.7% | 53.4% | 62.9% | 46.4% | 52.9% | |
| Capex / Sales | 1.6% | 3.7% | 3.2% | 2.4% | 2.4% | |
| SG&A / Sales | 24.8% | 24.7% | 25.4% | 23.7% | 24.4% | |
| R&D / Sales | 19.9% | 25.7% | 27.5% | 25.5% | 31.0% | |
| Stock comp / Sales | 3.0% | 3.0% | 2.7% | 2.5% | 2.2% | |
| Intangibles / Total assets | 53.2% | 57.6% | 54.3% | 30.9% | 33.4% | |
| Days sales outstanding | 69d | 70d | 78d | 77d | 65d | |
| Days payables outstanding | 54d | 67d | 58d | 79d | 102d | |
| Operating cycle | 343d | 459d | 442d | 292d | 299d | |
| Cash conversion cycle | 288d | 392d | 384d | 213d | 197d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years
Employee count
Peer market caps
Recent news
- 2026-08-06 Biogen Completes Acquisition of RayThera Inc. CAMBRIDGE, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced the completion of the acquisition of RayThera Inc., a privately held biotechnology company focused on discovering and developing small-molecule therapies in immunology.
- 2026-08-01 Biogen Inc. $BIIB Shares Acquired by Amundi Amundi increased its stake in Biogen Inc. (NASDAQ: BIIB) by 38.2% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 790,827 shares of the biotechnology company''s stock after buying an additional 218,398 shares during the period. Amundi owned about 0.54%
- 2026-07-29 Why Biogen Stock Topped the Market Today It handily beat analyst estimates on both the top and bottom lines. Investors didn''t even mind a cut in adjusted net income guidance.
- 2026-07-29 Biogen Inc. (BIIB) Q2 2026 Earnings Call Transcript Biogen Inc. (BIIB) Q2 2026 Earnings Call Transcript
- 2026-07-29 Biogen Boosts Profit Forecast with Growth Across Alzheimer''s, Rare Disease Portfolio Biogen Inc. (NASDAQ:BIIB) stock is trading higher on Wednesday after the company reported second-quarter adjusted earnings of $3.60 per share, beating the consensus of $2.96.
- 2026-07-29 Q2 Earnings Season in Full Swing Pre-market futures are flat-to-down ahead of today''s open, with overseas turbulence in the memory chip market reverberating on domestic shores. We also see something of a hesitation in trading ahead of this afternoon''s Fed decision on interest rates.
- 2026-07-29 Biogen''s Q2 Earnings Beat, New Drugs Drive Sales, 2026 Guidance Raised Biogen tops Q2 earnings and revenue estimates as growth drugs fuel sales, offset MS declines, and support a higher 2026 revenue and EPS outlook.
- 2026-07-29 Investors Await Fed Decision Today A quarter-points rate hike has been bandied about as a possibility today.
- 2026-07-29 Biogen: The Turnaround Is Real Enough To Buy (Rating Upgrade) Biogen Inc. is upgraded to ''Buy'' as strategic acquisitions and pipeline progress offset multiple sclerosis portfolio erosion. Q2 revenue grew 3% Y/Y, aided by Apellis acquisition, rare disease, and Alzheimer''s collaboration, with LEQEMBI gaining global traction. Felzartamab''s multi-indication potential and upcoming pivotal trial readouts underpin BIIB''s long-term growth prospects.
- 2026-07-29 Biogen (BIIB) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates Although the revenue and EPS for Biogen (BIIB) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.